Improved survival with clinical guidelines?: Evaluation of a quality register linked to clinical guidelines for ovarian cancer in the western health care region in Sweden between 1 September 1993 and 1 June 1998

被引:12
作者
Åkeson, M [1 ]
Zetterqvist, BM
Holmberg, E
Horvath, G
机构
[1] SAS, Dept Obstet & Gynecol, SE-50182 Boras, Sweden
[2] NAL, Dept Obstet & Gynecol, Trollhattan, Sweden
[3] Oncol Ctr Western Hlth Care, Gothenburg, Sweden
[4] Sahlgrenska Univ Hosp, Dept Gynecol Oncol, Gothenburg, Sweden
关键词
5-year survival; clinical guidelines; ovarian cancer; quality register;
D O I
10.1111/j.0001-6349.2005.00850.x
中图分类号
R71 [妇产科学];
学科分类号
100211 [妇产科学];
摘要
Background. New clinical guidelines (CGs) for ovarian cancer in the western health care region in Sweden were established, beginning in September 1993 and still in effect. Methods. A retrospective evaluation of 5 years of quality registration linked to CGs for ovarian cancer in this region was undertaken. The study material comprised 718 patients. Relative survival rates for the studied patients were compared with National Cancer Register data for the western health care region during the same period. The National Cancer Register data were also used to compare survival rate during the studied period and the preceding 5-year period. Results. Relative 5-year survival rate in our material was 46.1%. Relative survival in western Sweden during the studied period was found to be improved compared with that during the preceding period (P < 0.02). Conclusions. The CGs have led to an improved, tighter organization, with fewer clinicians in special 'tumor teams' performing more aggressive tumor reduction surgery. Chemotherapy prescription is centralized, while the actual administration is decentralized. This has probably been important for the good 5-year survival results.
引用
收藏
页码:1113 / 1118
页数:6
相关论文
共 20 条
[1]
CARBOPLATIN IN COMBINATION WITH EPIRUBICIN AND CYCLOPHOSPHAMIDE IN PATIENTS WITH ADVANCED OVARIAN-CANCER - A PHASE-II STUDY [J].
ANDERSSON, H ;
FRIBERG, LG ;
HORVATH, G ;
JOHANSSON, O ;
AKESSON, M ;
WESTBERG, R .
ACTA ONCOLOGICA, 1995, 34 (06) :821-827
[2]
[Anonymous], 2003, Stata Statistical Software
[3]
Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer [J].
Bristow, RE ;
Montz, FJ ;
Lagasse, LD ;
Leuchter, RS ;
Karlan, BY .
GYNECOLOGIC ONCOLOGY, 1999, 72 (03) :278-287
[4]
A population-based study of patterns of care for ovarian cancer: Who is seen by a gynecologic oncologist and who is not? [J].
Carney, ME ;
Lancaster, JM ;
Ford, C ;
Tsodikov, A ;
Wiggins, CL .
GYNECOLOGIC ONCOLOGY, 2002, 84 (01) :36-42
[5]
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study [J].
Eisenkop, SM ;
Friedman, RL ;
Wang, HJ .
GYNECOLOGIC ONCOLOGY, 1998, 69 (02) :103-108
[6]
THE IMPACT OF SUBSPECIALTY TRAINING ON THE MANAGEMENT OF ADVANCED OVARIAN-CANCER [J].
EISENKOP, SM ;
SPIRTOS, NM ;
MONTAG, TW ;
NALICK, RH ;
WANG, HJ .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :203-209
[7]
Outcomes in surgery for ovarian cancer [J].
Elit, L ;
Bondy, SJ ;
Paszat, L ;
Przybysz, R ;
Levine, M .
GYNECOLOGIC ONCOLOGY, 2002, 87 (03) :260-267
[8]
A COMPUTER-PROGRAM PACKAGE FOR RELATIVE SURVIVAL ANALYSIS [J].
HAKULINEN, T ;
ABEYWICKRAMA, KH .
COMPUTER PROGRAMS IN BIOMEDICINE, 1985, 19 (2-3) :197-207
[9]
HEINTZ APM, 1998, CANC WOMEN
[10]
HENIC E, 1998, LAKARTIDNINGEN, V22, P2574